Asset Details
Do you wish to reserve the book?
Rethinking Medication Safety in Pregnancy and Infancy: How Target Trial Emulation and Real-World Data Bridge the Evidence Gap
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Rethinking Medication Safety in Pregnancy and Infancy: How Target Trial Emulation and Real-World Data Bridge the Evidence Gap
Do you wish to request the book?
Rethinking Medication Safety in Pregnancy and Infancy: How Target Trial Emulation and Real-World Data Bridge the Evidence Gap
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Rethinking Medication Safety in Pregnancy and Infancy: How Target Trial Emulation and Real-World Data Bridge the Evidence Gap
2025
Overview
The exclusion of pregnant women and infants from many randomized controlled trials (RCTs) has left critical gaps in medication safety, complicating clinical decision-making during these sensitive life stages. This commentary explores target trial emulation using real-world data as a robust alternative for advancing medication safety research when RCTs are not feasible.
Target trial emulation replicates the design principles of RCTs within observational data, accounting for the dynamic nature of medication exposure across gestational stages and adjusting for time-varying confounders. While challenges such as unmeasured confounding, selection bias, and violations of positivity assumptions remain, this method provides crucial insights to address current evidence gaps.
Information on medication exposure effects will be obtained, which will inform safer medication guidelines in pregnancy and infancy. Future research integrating artificial intelligence–driven tools, open science practices, and robust data governance frameworks will further strengthen the reliability and impact of target trial emulation. Multinational collaboration and data sharing across diverse sources will accelerate the generation of evidence, ultimately advancing medication safety.
Target trial emulation, leveraging real-world data, is a promising alternative when traditional clinical trials are not feasible. This approach promotes safer medication use and improves health outcomes for mothers and infants.
Many clinical trials exclude pregnant women and infants, leaving critical gaps in understanding medication safety during pregnancy and early life. Target trial emulation, which applies clinical trial principles to real-world data, offers a promising alternative when traditional trials are not feasible. This method allows researchers to study how medications affect pregnant women and babies at different stages of pregnancy while also considering factors that change over time. While there are still challenges, like unmeasured factors and bias remain, target trial emulation helps fill these knowledge gaps. Future advancements, including AI, Open Science, enhanced data sharing, and international collaboration, can further enhance this method's ability to improve the safety of medications for mothers and infants worldwide.
[Display omitted]
